This pathophysiology diagram illustrates the neural pathways of nociceptive processing and the mechanisms of spinal cord stimulation (SCS). The graphic features a sagittal cutaway of the human brain and a cross-section of the spinal cord. Key intracranial structures labeled include the prefrontal cortex, anterior cingulate cortex (highlighted in red), primary somatosensory cortex, insula, thalamus, and amygdala. The brainstem is detailed with the periaqueductal gray and ventrolateral medulla, indicating the descending inhibitory system. At the spinal level, the diagram shows the dorsal horn and its interaction with Aβ and Aδ/C nerve fibers following a 'nerve injury'. The visual highlights the ascending spinothalamic tract and descending pathways that facilitate segmental spinal inhibition. Key physiological concepts depicted include gate control theory, orthodromic and antidromic transduction, and cortical modulation. This educational material is designed to demonstrate how neuromodulation through SCS impacts pain signaling and inhibitory feedback loops between the peripheral nervous system and the central nervous system.

This pathophysiology diagram illustrates the complex relationship between DPP4 inhibitors, glycemic control, and SARS-CoV-2 infection outcomes. The central mechanism depicts SARS-CoV-2 virions utilizing two cell-surface pathways for 'Viral Entry' into a 'Target Cell': the DPP4 protease (green) and ACE2 glycosylation sites (blue). The diagram outlines the systemic effects of DPP4 inhibition through two primary branches. First, the inhibition of DPP4 leads to increased Glucagon-like Peptide 1 (GLP1), which reduces hyperglycemia, potentially mitigating SARS-CoV-2 infection. Second, DPP4 inhibition increases Stromal Derived Factor 1 (SDF1), which elevates mast cell levels. This increase in mast cells presents a dual clinical implication: it may inhibit viral entry but simultaneously promote proinflammatory cytokine release, contributing to 'Severe COVID-19 Disease.' The chart effectively summarizes the therapeutic paradox where glycemic benefits and viral entry inhibition must be weighed against the risk of exacerbated inflammatory responses in COVID-19 management.

Educational figure illustrating the molecular mechanism and experimental model of retinal detachment and Rho-kinase (ROCK) inhibition. Panel A is a pathophysiology diagram showing that Fasudil inhibits ROCK, which normally activates LIMK and Myosin Light Chain. This inhibition prevents cofilin phosphorylation and actomyosin contraction, theoretically stopping photoreceptor axon retraction. Panels B and C are clinical specimen photographs of porcine eyecups (right and left eyes) used for in vivo studies. The images show the posterior segment with anatomical markers: S (Superior), I (Inferior), T (Temporal), N (Nasal), and OD (Optic Disc). Yellow squares indicate sample collection areas for morphological analysis: 'BC' and 'FC' represent attached retinal control areas, while 'BD' (control BSS) and 'FD' (Fasudil-treated) indicate areas of iatrogenic retinal detachment created in the inferior-nasal quadrant. The visual contrast between attached and detached retinal folds is evident. This material is designed for advanced ophthalmic research on neuroprotection and synaptic remodeling following retinal injury.

A pathophysiology diagram illustrating the mechanism of peripheral pain control via leukocyte-derived enkephalins (ENKs). The visual depicts three primary anatomical regions: damaged peripheral tissue, the spinal cord (axial cross-section), and the brain. In the periphery, opioid-containing leukocytes undergo extravasation from blood vessels, attracted by chemokines produced at the site of tissue damage. These leukocytes enter the DOPr-ENK neuroimmune network and release enkephalins. These ENKs bind to the peripheral endings of primary nociceptors (dorsal root ganglion cell axons). This interaction leads to a functional inhibition shown at the spinal level: there is a 'decreased release of neurotransmitters' from the primary afferent into the dorsal horn. The resulting effect is depicted by a red arrow labeled 'poor transmission of pain signals' ascending toward the brain, illustrating the analgesic effect of immune-mediated opioid release in response to inflammatory peripheral damage.

A clinical photograph illustrating a Transcutaneous Electrical Nerve Stimulation (TENS) setup for pain management. The image displays a portable, handheld, battery-operated TENS device held in a patient's hand. The device is black with physical control knobs for adjusting 'Pulse Width' and 'Pulse Frequency,' alongside a 'Timer' switch and a yellow intensity dial. Labeled electrode lead wires extend from the top of the device to two square, white, self-adhering electrode pads placed on the patient's anterior forearm. This procedural image demonstrates the correct positioning for delivering pulsed electrical currents across the skin's surface to stimulate peripheral nerves (A-beta fibers) for symptomatic pain relief. The visual focuses on the integration of hardware, skin interface, and user-adjustable settings in physical therapy and rehabilitation medicine.

This clinical photograph illustrates a procedural setup for Low-Frequency Transcutaneous Electrical Nerve Stimulation (LF TENS) of the tibial nerve. The subject is positioned prone on a medical table. A stationary rectangular cathode is fixed with white adhesive tape over the nerve in the popliteal fossa of the lower leg. A clinician is shown manually applying a mobile, pen-like anode electrode, moving it along the posterior calf in a proximal-to-distal direction to target the nerve pathway. Both electrodes are connected to a digital medical stimulation device positioned in the foreground. The device interface displays a timer (08:10), wave parameters, and clinical settings regulated by a large central rotary dial and illuminated functional buttons. This procedure is commonly utilized in physical therapy and neurology for managing neuropathic pain, such as diabetic painful distal axonal neuropathy, by inducing painless muscle contractions to modulate pain perception.

Clinical photograph of a transcutaneous electrical nerve stimulation (TENS) device kit, commonly used in physical therapy, pain management, and experimental medicine—such as parotid gland stimulation to increase salivary flow. The components are arranged on a green sterile field and include a dual-channel TENS control unit (model MH8000), four square self-adhesive electrode pads with integrated lead wires, two coiled black electrical cables with dual-terminal connectors, a roll of micropore medical tape for securing electrodes, and a black hard-shell carrying case labeled 'MEDICAL DEVICE'. The blue control unit features a digital LCD screen and tactile interface buttons for adjusting pulse rate, pulse width, and intensity (0-80mA). This visual serves to illustrate the equipment required for non-invasive neurostimulation procedures in both clinical and research settings.